Patterns of progression in patients treated for immuno-oncology antibodies combination.

Alice Bernard-TessierCapucine BaldiniEduardo CastanonPatricia MartinStéphane ChampiatAntoine HollebecqueSophie Postel-VinayAndreea VargaRastilav BahledaAnas GazzahJean-Marie MichotVincent RibragJean-Pierre ArmandAurélien MarabelleJean-Charles SoriaChristophe MassardSamy Ammari

Published in: Cancer immunology, immunotherapy : CII (2020)

Pseudoprogression and dissociated response are uncommon patterns of progression. Their prevalence should be balanced with the rate of real progressing patients treated beyond progression. Prognosis or on-treatment biomarkers are needed to identify early patients who will benefit from immunotherapy.

Keyphrases

palliative care
combination therapy